Thrombosis Research
Volume 124, Issue 4 , Pages 427-432 , September 2009

Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia

  • Evelien Heylen

      Affiliations

    • Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium
    • Both authors contributed equally to this study.
    • E. Heylen is a research assistant of the Fund for Scientific Research Flanders (FWO-Vlaanderen).
    • ,
  • Predrag Miljic

      Affiliations

    • Institute of Hematology, University Clinical Centre of Serbia, Belgrade, Serbia
    • Both authors contributed equally to this study.
    • ,
  • Johan Willemse

      Affiliations

    • Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium
    • ,
  • Valentina Djordjevic

      Affiliations

    • Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia
    • ,
  • Dragica Radojkovic

      Affiliations

    • Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia
    • ,
  • Milica Colovic

      Affiliations

    • Institute of Hematology, University Clinical Centre of Serbia, Belgrade, Serbia
    • ,
  • Ivo Elezovic

      Affiliations

    • Institute of Hematology, University Clinical Centre of Serbia, Belgrade, Serbia
    • ,
  • Dirk Hendriks

      Affiliations

    • Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium
    • Corresponding Author InformationCorresponding author. Laboratory of Medical Biochemistry, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium. Tel.: +32 3 820 27 27; fax: +32 3 820 27 45.

Received 2 September 2008 ,Revised 8 January 2009 ,Accepted 12 January 2009.

References 

  1. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  2. Rosendorff A, Dorfman D. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med. 2007;131:866–871
  3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  4. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost. 2000;83:817–821
  5. Zoller B, Holm J, Svensson PJ, Dahlback B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein s deficiency. Thromb Haemost. 1996;75:270–274
  6. Martinelli I, Bottasso B, Duca F, Faioni E, Manucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 1996;75:703–705
  7. Coppens M, Folkeringa N, Teune MJ, Hamulyak K, van der Meer J, Prins MH, et al. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost. 2007;5:1444–1448
  8. Gouin-Thibault I, Arkam R, Nassiri S, de la Tourette A, Conard J, Horellou MH, et al. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res. 2002;107:7–11
  9. Hendriks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem. 1989;27:277–285
  10. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477–14484
  11. Hendriks DF, Willemse JL. Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). J Thromb Haemost. 2006;4:261–262
  12. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176–27181
  13. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26:2445–2453
  14. Bazjar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603–16608
  15. Willemse JL, Hendriks DF. A role for procarboxypeptidase U (TAFI) in thrombosis. Front Biosci. 2007;12:1973–1987
  16. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describint the prothrombotic effect associated woth factor V Leiden. J Biol Chem. 1996;271:22949–22952
  17. Parker AC, Mundada LV, Schmair AH, Fay WP. Factor V Leiden inhibitis fibrinolysis in vivo. Circulation. 2004;110:3594–3598
  18. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occuring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 2002;277:1021–1030
  19. Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, et al. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demostrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J. 2006;273:778–792
  20. Folkeringa N, Coppens M, Veeger NJG, Bom VJ, Middeldorp S, Hamulyak K, et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost. 2008;100:38–44
  21. Libourel EJ, Bank I, Meinardi JR, Balje -Volkers CP, Hamulyak K, Middeldorp S, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002;87:1068–1073
  22. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855–2859
  23. Willemse JL, Leurs JR, Hendriks DF. Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. J Thromb Haemost. 2005;3:2353–2355
  24. Willemse JL, Matus V, Heylen E, Mezzano D, Hendriks DF. Influence of the Thr325Ile polymorphism on procarboxypeptidase U (TAFI) activity-based assays. J Thromb Haemost. 2007;5:872–875
  25. Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16:1163–1169
  26. Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol. 2003;122:958–965
  27. Woolf B. On estimating the relation between blood group and disease. Am J Hum Genet. 1955;19:251–253
  28. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 2001;98:1992–1993
  29. Antovic JP, Blombäck M. Thrombin-activable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Thromb Res. 2002;106:59–62
  30. Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, et al. Reduced activity of TAFI (thrombin-activable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol. 2000;108:518–523
  31. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611–1617
  32. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800–2802
  33. Simioni P, Prandoni P, Lensing AWA, Manfrin D, Tormene D, Gavasso S, et al. Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep vein thrombosis. Blood. 2000;96:3329–3333
  34. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773–3776
  35. Morange P, Henry M, Frére C, Juhan-Vague I (HIFMECH study group). Thr325Ile polymorphism in the TAFI gene does not influence the risk of myocardial infarction. Blood. 2002;99:1878–1879

PII: S0049-3848(09)00029-2

doi: 10.1016/j.thromres.2009.01.005

Thrombosis Research
Volume 124, Issue 4 , Pages 427-432 , September 2009

Article Tools